ENGLEWOOD, Colo., Sept. 08, 2017 -- Innospec Inc (Nasdaq:IOSP) today announced that it has concluded the registration of its new wholly-owned enterprise in China.
Innospec Chemical (Beijing) Co. Ltd. was formally registered in July, and will begin full operation on October 1, 2017, replacing Innospec’s previous representative office.
Patrick S. Williams, President and Chief Executive Officer, said “This is the next step in gradually extending Innospec’s global footprint as the demand for specialty chemicals continues to develop, particularly in China. We will be able to trade and manage inventory locally. This will enable us to grow our business in this expanding and thriving market.”
Sean Pang, Regional Director for Innospec in Asia Pacific, added “We are delighted that we will be able to improve our service to customers across all of our businesses in China – for Fuel Specialties, Performance Chemicals and Oilfield Services. We look forward to working with our customers to create profitable solutions for the long-term growth of their business.”
About Innospec Inc.
Innospec Inc. is an international specialty chemicals company with approximately 1800 employees in 23 countries. Innospec manufactures and supplies a wide range of specialty chemicals to markets in the Americas, Europe, the Middle East, Africa and Asia-Pacific. The Fuel Specialties business specializes in manufacturing and supplying fuel additives that improve fuel efficiency, boost engine performance and reduce harmful emissions. Oilfield Services provides specialty chemicals to all elements of the oil & gas exploration and production industry. The Performance Chemicals business creates innovative technology-based solutions for our customers in the Personal Care, Home Care, Agrochemical, Mining and Industrial markets. Octane Additives produces octane improvers to enhance gasoline.
Forward-Looking Statements
This press release contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts included or incorporated herein may constitute forward-looking statements. Such forward-looking statements include statements (covered by words like “expects,” “estimates,” “anticipates,” “may,” “believes,” “feels” or similar words or expressions), for example, which relate to earnings, growth potential, operating performance, events or developments that we expect or anticipate will or may occur in the future. Although forward-looking statements are believed by management to be reasonable when made, they are subject to certain risks, uncertainties and assumptions and our actual performance or results may differ materially from these forward-looking statements. Additional information regarding risks, uncertainties and assumptions relating to Innospec and affecting our business operations and prospects are described in Innospec’s Annual Report on Form 10-K for the year ended December 31, 2016 and other reports filed with the U.S. Securities and Exchange Commission. You are urged to review our discussion of risks and uncertainties that could cause actual results to differ from forward-looking statements under the heading "Risk Factors” in such reports. Innospec undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact: Brian Watt Innospec Inc. +44-151-355-3611 [email protected]


SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Apple Turns 50: From Garage Startup to AI Crossroads
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 



